IL-17 Binding Compounds and Medical Uses Thereof

Abstract

The present invention relates to new IL-17 inhibiting polypeptides, corresponding fusion proteins, compositions and medical uses thereof.

1 - 30 . (canceled) 
     
     
         31 . A polypeptide comprising an amino acid sequence selected from the group consisting of:
 (a)
   (G/E)VTLFVALYDY-(X) a -D-(X) b —SFHKGEKF-(X) c -I-(X) d -G-(X) e -WW-(X) f -A-(X) g -SLTTG-(X) h GYIPSNYVAPVDSIQ  (I)
 
 wherein a to h are 0 to 20, 
   (b) an amino acid sequence having at least 70% amino acid sequence identity to (a);   (c) an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to the complementary strand of a nucleic acid coding for (a);   (iv) a fragment or functional derivative which binds to IL-17 A of (a)-(c) derivable by substitution, addition, and/or deletion of at least one amino acid,
 wherein said polypeptide binds to IL-17A. 
   
     
     
         32 . The polypeptide of  claim 31 , wherein said polypeptide is selected from the group consisting of SEQ ID NOs: 1-119 or a functional derivative thereof. 
     
     
         33 . A fusion protein comprising a polypeptide of  claim 31  fused to a pharmaceutically and/or diagnostically active component. 
     
     
         34 . The fusion protein according to  claim 33 , wherein said component is
 (a) a cytokine,   (b) a toxic compound,   (c) is a chemokine,   (d) a fluorescent dye,   (e) a photosensitizer,   (f) a pro-coagulant factor,   (g) an enzyme for prodrug activation,   (h) a radionuclide, or   (i) a functional Fc domain.   
     
     
         35 . The polypeptide of  claim 31 , further comprising a component modulating serum half-life, preferably a component selected from the group consisting of polyethylene glycol (PEG), immunoglobulin, and albumin-binding peptides. 
     
     
         36 . The fusion protein of  claim 33 , further comprising a component modulating serum half-life, preferably a component selected from the group consisting of polyethylene glycol (PEG), immunoglobulin, and albumin-binding peptides. 
     
     
         37 . A polypeptide comprising multimers of the polypeptide of  claim 31 . 
     
     
         38 . A polypeptide comprising multimers of the fusion protein of  claim 33 . 
     
     
         39 . An isolated nucleic acid, comprising
 (a) a nucleic acid encoding a polypeptide according to  claim 31 , preferably encoding (G/E)VTLFVALYDY-(X) 6 -D-(X)-SFHKGEKF-(X) 1 -I-(X) 5-7 -G-(X) 1 -WW-(X)-A-(X)-SLTTG-(X) 1-2 -GYIPSNYVAPVDSIQ;   (b) a nucleic acid having a sequence with at least 70% sequence identity to the nucleic acid sequence of (a);   (c) a nucleic acid that hybridizes to the complementary strand of a nucleic acid of (a) or (b);   (d) a nucleic acid, wherein said nucleic acid is derivable by substitution, addition and/or deletion of one of the nucleic acids of (a), (b) or (c);   (e) a fragment of any one of the nucleic acids of (a) to (d), that hybridizes to the complementary strand of a nucleic acid of (a) coding for a polypeptide according to  claim 31 .   
     
     
         40 . The nucleic acid of  claim 39 , wherein said nucleic acid is operably linked to a promoter. 
     
     
         41 . A recombinant vector comprising a nucleic acid of  claim 39 . 
     
     
         42 . A host cell comprising the recombinant vector of  claim 41 . 
     
     
         42 . A monoclonal antibody that specifically binds a polypeptide of  claim 31 . 
     
     
         43 . A hybridoma cell line expressing a monoclonal antibody of  claim 42 . 
     
     
         44 . A pharmaceutical composition comprising the polypeptide of  claim 31 . 
     
     
         45 . A pharmaceutical composition comprising the nucleic of  claim 39 . 
     
     
         46 . A pharmaceutical composition comprising the recombinant vector of  claim 41 . 
     
     
         47 . A method for treating a disease or medical condition selected from the group consisting of IL-17A- and Th17-related diseases or medical conditions comprising administering the polypeptide of  claim 31 . 
     
     
         48 . The method of  claim 47 , wherein the disease or medical condition is selected from inflammatory, autoimmune and/or bone loss-related diseases and medical conditions. 
     
     
         49 . A method for treating a disease or medical condition selected from the group consisting of IL-17A- and Th17-related diseases or medical conditions comprising administering the polypeptide of  claim 32 . 
     
     
         50 . The method of  claim 49 , wherein the disease or medical condition is selected from inflammatory, autoimmune and/or bone loss-related diseases and medical conditions. 
     
     
         51 . A method for treating a disease or medical condition selected from the group consisting of IL-17A- and Th17-related diseases or medical conditions comprising administering the fusion protein of  claim 33 . 
     
     
         52 . The method of  claim 51 , wherein the disease or medical condition is selected from inflammatory, autoimmune and/or bone loss-related diseases and medical conditions. 
     
     
         53 . A method for treating a disease or medical condition selected from the group consisting of IL-17A- and Th17-related diseases or medical conditions comprising administering the nucleic acid of  claim 39 . 
     
     
         54 . The method of  claim 53 , wherein the disease or medical condition is selected from inflammatory, autoimmune and/or bone loss-related diseases and medical conditions. 
     
     
         55 . A method for treating a disease or medical condition selected from the group consisting of IL-17A- and Th17-related diseases or medical conditions comprising administering the recombinant vector of  claim 41 . 
     
     
         56 . The method of  claim 55 , wherein the disease or medical condition is selected from inflammatory, autoimmune and/or bone loss-related diseases and medical conditions.